Noonan syndrome other diagnostic studies

Revision as of 02:06, 15 November 2013 by Rim Halaby (talk | contribs) (→‎Overview)
Jump to navigation Jump to search

Noonan syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Noonan syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

ECG Findings

Other Diagnostic Studies

Treatment

Management & Follow-up

Genetic Counseling

Case Studies

Case #1

Noonan syndrome other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Noonan syndrome other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Noonan syndrome other diagnostic studies

CDC on Noonan syndrome other diagnostic studies

Noonan syndrome other diagnostic studies in the news

Blogs on Noonan syndrome other diagnostic studies

Directions to Hospitals Treating Noonan syndrome

Risk calculators and risk factors for Noonan syndrome other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Serge Korjian

Overview

Although not always required, genetic testing can confirm the diagnosis but not exclude it. Classically PTPN11 mutations can be seen in approximately half of the patients.

Other Diagnostic Studies

Genetic Analysis

Eight genes all involved in the RAS/MAP kinase pathway have been identified as possible causes for Noonan syndrome. In order of prevalence, the causative mutations involve the following genes: PTPN11, SOS1, RAF1, SHOC2, KRAS, BRAF, NRAS, and CBL. Definitive diagnosis is usually with genetic testing which is commonly by chip-based sequencing, to test all the genes that could be involved simultaneously. [1] If chip based-testing is not available, PTPN11 sequencing should be performed first. If PTPN11 is negative considering other genes can be based on the clinical findings detailed below:[2]

  • SOS1: Absent developmental delays, normal stature, skin and hair findings
  • RAF1: Hypertrophic cardiomyopathy
  • KRAS: Significant developmental delay and cognitive impairment
  • SHOC2: Thin, slow-growing, sparse hair

Not all patients require genetic testing as the diagnosis is mostly clinical. A positive genetic test can confirm the diagnosis, but a negative test cannot exclude it.[2]

References

  1. Roberts AE, Allanson JE, Tartaglia M, Gelb BD (2013). "Noonan syndrome". Lancet. 381 (9863): 333–42. doi:10.1016/S0140-6736(12)61023-X. PMID 23312968.
  2. 2.0 2.1 Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME; et al. (2010). "Noonan syndrome: clinical features, diagnosis, and management guidelines". Pediatrics. 126 (4): 746–59. doi:10.1542/peds.2009-3207. PMID 20876176.

Template:Phakomatoses and other congenital malformations not elsewhere classified


Template:WikiDoc Sources